By Finance Pulse in KeyInfo —

Eli Lilly's Zepbound Approval Impacts ResMed, Inspire Stocks

FDA's approval of Eli Lilly's Zepbound for obstructive sleep apnea hits ResMed and Inspire Medical Systems stocks. Explore the healthcare market shift.

A visually compelling image depicting a stock market graph with a background of medical symbols, emp
Eli Lilly's Zepbound Approval Impacts ResMed, Inspire Stocks

ResMed and Inspire Medical Systems stocks fell after FDA approved Eli Lilly's weight-loss drug Zepbound for obstructive sleep apnea.

Source